The purpose of this study is to compare any good and bad effects patients with early stage non-small cell lung cancer that was surgically removed may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug).
This study is for patients that participated in the A151216 screening study and were found to have a mutation of a gene called EGFR (Epidermal Growth Factor Receptor). We are trying to find out if this mutation could help us make decisions about what type of treatment is best for people with early stage non-small cell lung cancer.
For more information, please visit the National Cancer Institute.
